MUC1 as a putative prognostic marker for prostate cancer

Biomarker Insights

Volumn 2008, Issue 3, 2008, Pages 303-315

  Strawbridge, Rona J ^a,b   Nistér, Monica ^a   Brismar, Kerstin ^a   Grönberg, Henrik ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies; Functional predictions; Isoforms; Mucin 1; Prostate cancer

Indexed keywords

MUCIN 1;

ALLELE; AMINO ACID SEQUENCE; CONTROLLED STUDY; DISEASE MARKER; DNA DETERMINATION; GENE FREQUENCY; GENOTYPE; HEREDITY; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL PROTEOMICS;

EID: 44449144439     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Andren, O., Fall, K., Andersson, S.O. et al. 2007. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br. J. Cancer, 97(6):730-4.
2. Arai, T., Fujita, K., Fujime, M. et al. 2005. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int. J. Urol., 12(7):654-61.
3. Baruch, A., Hartmann, M., Yoeli M. et al. 1999. The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. Cancer Res., 59(7):1552-61.
4. Baruch, A., Hartmann, M., Zrihan-Licht, S. et al. 1997. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int. J. Cancer, 71(5):741-9.
5. Bendtsen, J.D., Nielsen, H., von Heijne, G. et al. 2004. Improved prediction of signal peptides: Signal P 3.0. J. Mol. Biol., 340(4):783-95.
6. Boeckmann, B., Blatter, M.C., Famiglietti, L. et al. 2005. Protein variety and functional diversity: Swiss-Prot annotation in its biological context. CR Biol., 328(10-11):882-99.
7. Burke, P.A., Gregg, J.P, Bakhtiar, B. et al. 2006. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. Int J. Oncol., 29(1):49-55.
8. Cozzi, P.J., Wang, J., Delprado, W. et al. 2005. MUC1, MUC2, MUC4, MUC5AC and MUG6 expression in the progression of prostate cancer. Clin. Exp. Metastasis, 22(7):565-73.
9. Engelmann, K., Kinlough, C.L., Muller, S. et al. 2005. Transmembrane and secreted MUC1 probes show trafficking-dependent changes in O-glycan core pro les. Glycobiology, 15(11):1111-24.
10. Falquet, L., Pagni, M., Bucher, P. et al. 2002. The PROSITE database, its status in. Nucleic Acids Res., 30(1):235-8.
11. Gasteiger, E., Gattiker, A., Hoogland, C. et al. 2003. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res., 31(13):3784-8.
12. HapMap (2005). www.hapmap.org.
13. Ho, S.B., Niehans, G.A., Lyftogt, C. et al. 1993. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res., 53(3):641-51,
14. Julian, J. and Carson, D.D. 2002. Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells. Biochem. Biophys. Res, Commun. 293(4):1183-90.
15. Kinlough, C.L., McMahan, R.J., Poland, P.A. et al. 2006, Recycling of MUC1 is dependent on its palmitoylation, J. Biol. Chem., 281(17):12112-22.
16. Kirschenbaum,A., Itzkowitz, S.H., Wang, J.P. et al. 1999. MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. Mol. Urol., 3(3) 163-8.
17. Lapointe, J., Li, C., Higgins, J.P. et al. 2004. Gene expression pro ling identies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 101(3):811-6.
18. Legrier, M. E., de Pinieux, G., Boye, K. et al. 2004. Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft. Br. J. Cancer. 90(3):710-7.
19. Levitin, F., Stem, O., Weiss, M. et al. 2005. The MUC1 SEA module is a self-cleaving domain. J Biol. Chem., 280(39):33374-86,
20. Li, C., Berx, G., Larsson, C. et al. 1999. Distinct deleted regions on chromosome segment 16q23-24 associated with metastases in prostate cancer. Genes Chromosomes Cancer. 24(3): 175-82.
21. Li, Y., Bharti, A., Chen, D. et al. 1998. Interaction of glycogen synthase kinase 3 beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol. Cell Biol. 18(12):7216-24.
22. Ligtenberg, M.J., Gennissen, A.M., Vos, H.L. et al. 1991. A single nucleotide polymorphism in an exon dictates allele dependent differential splicing of episialin mRNA. Nucleic Acids Res., 19(2):297-301.
23. Macao, B., Johansson, D.G., Hansson, G.C. et al. 2006. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat. Struct. Mol. Biol. 13(1):71-6.
24. Mitchell, S., Abel, P., Madaan, S. et al. 2002. Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia, 4(1):9-18, NCBI www.ncbi.nlm.nih.gov.
25. Notredame, C., Higgins, D.G. and Heringa, J. 2000. T-Coffee: A novel method for fast and accurate multiple sequence alignment. J. Mol. Biol., 302(1) 205-17.
26. Obermair, A., Schmid, B.C., Packer, L.M. et al. 2002. Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int. J. Cancer, 100(2): 166-71.
27. O'Connor, J.C., Julian, J., Lim, S. D. et al. 2005. MUC1 expression in human prostate cancer cell lines and primary tumors. Prostate Cancer Prostatic Dis., 8(1):36-44.
28. Palmai-Pallag, T., Khodabukus, N., Kinarsky, L. et al. 2005. The role of the SEA (sea urchin sperm protein, enterokinase and agrin) module in cleavage of membrane-tethered mucins. Febs J. 272(11):2901-11.
29. Papadopous, I., Sivridis, E., Giatromanolaki, A. et al. 2001. Tumor angio-genesis is associated with MUC1 overexpression and loss of prostate- specic antigen expression in prostate cancer. Clin. Cancer Res., 7(6): 1533-8.
30. Ponting, C.P., Schultz, J., Milpetz, F. et al. 1999. SMART: identication, and annotation of domains from signalling and extracellular protein sequences. Nucleic Acids Res., 27(1):229-32. PPSearch http://www.ebi.ac.uk/ppsearch/.
31. Schmid, B. C., Buluwela, L., Liu, Q. et al. 2002. Expression of MUC1 splice variants correlates with invasive growth of breast cancer cell lines. Breast Cancer Res. Treat., 76(3):211-9.
32. Schut, I.C., Waterfall, P.M., Ross, M. et al. 2003. MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue. BJU Int., 91(3):278-83.
33. Singh, A.P., Chauhan, S.C., Bafna, S. et al. 2006. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate. 66(4) 421-9.
34. Smith, J.R, Freije, D., Carpten, J.D. et al. 1996. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science, 274(5291):1371-4.
35. Thompson, E.J., Shimmugam, K, Hattrup, C.L. et al. 2006. Tyrosines in the MUC1 cytoplasmic tail modulate trascription via the extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB pathways. Mol. Cancer Res., 4(7):489-97.
36. Truant, S., Bruyneel, E., Gouyer, V. et al. 2003. Requirement of both mucins and proteoglycans in cell-cell dissociation and invasiveness of colon carcinoma HT-29 cells. Int. J. Cancer, 104(6)A3-94.
37. Uhlen, M. 2007. Mapping the human proteome using antibodies. Mol. Cell Proteomics, 6(8):1455-6.
38. Wei, X., Xu, H. and Kufe, D. 2005. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell., 7(2) 167-78.
39. Wei, X., Xu, H. and Kufe, D. 2006. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol. Cell., 21(2):295-305.
40. Wesseling, J., van der Valk, S.W and Hilkens, 11996. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell., 7(4):565-77.
41. Zhang, H.K., Zhang, Q.M., Zhao, TH. et al. 2004. Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance. World J. Gastroenterol., 10(20):3044-7.